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Monoterpenes are found in the essential oils of many plants including fruits, vegetables, and
herbs. They prevent the carcinogenesis process at both the initiation and promotion/progression
stages. In addition, monoterpenes are effective in treating early and advanced cancers.
Monoterpenes such as limonene and perillyl alcohol have been shown to prevent mammary,
liver, lung, and other cancers. These compounds have also been used to treat a variety of rodent
cancers, including breast and pancreatic carcinomas. In addition, in vitro data suggest that they
may be effective in treating neuroblastomas and leukemias. Both limonene and perillyl alcohol are
currently being evaluated in phase clinical trials in advanced cancer patients. The monoterpenes
have several cellular and molecular activities that could potentially underlie their positive
therapeutic index. The monoterpenes inhibit the isoprenylation of small G proteins. Such
inhibitions could alter signal transduction and result in altered gene expression. The results of a
new gene expression screen-subtractive display-have identified or confirmed several up- or
downregulated genes in regressing mammary carcinomas. For example, these regressing
tumors overexpress the mannose 6-phosphate/IGF 11 receptor. The product of this gene both
degrades the mammary tumor mitogen IGF 11 and activates the cytostatic factor TGF-f. These
and other alterations in the gene expression of mammary carcinomas lead to a G1 cell cycle
block, followed by apoptosis, redifferentiation, and finally complete tumor regression in which
tumor parenchyma is replaced by stromal elements. It is likely that monoterpenes prevent
mammary cancer during their progression stage by mechanisms similar to those that occur
during therapy. In contrast, prevention of mammary cancer by polycyclic hydrocarbons such as
7,12-dimethylbenzlalanthracene occur by the induction of detoxifying phase 11 hepatic enzymes.
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Anticancer agents have traditionally been
classified as those that are targeted either
at the prevention or treatment of cancer.
Prevention agents are classified as those
that block initiation or suppress promo-
tion/progression. Cancer therapeutic drugs
today are mainly cytotoxic. They act to
directly or indirectly kill cancer cells. More
recently cytostatic agents that block cell
division with or without stimulating differ-
entiation are being used in and developed
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for use in cancer patients. Based on this
classification it is possible for agents to
bridge cancer prevention and therapy.
An example of a group of such anti-
cancer agents are the monoterpenes.
Monoterpenes are naturally occurring
hydrocarbons composed ofthe condensa-
tion of two isoprenes. They are widely dis-
tributed in the plant kingdom and are best
known in plant essential oils. Two mono-
terpenes that have efficacy in both cancer
prevention and therapy are limonene and
perillyl alcohol. These monocyclic mono-
terpenes prevent several forms ofcancer by
blocking initiation (1). For example,
limonene has been shown to block mam-
mary cancer induced by 7,12-dimethyl-
benz[a]anthracene (DMBA) in rats (2). In
addition to this blocking activity, limonene
and perillyl alcohol have been shown to
have suppressing activity in both mammary
(3,4) cancer models. When given post-
initiation, they prevent the progression of
cancer in these organs following carcinogen
exposure. Finally, both limonene and
perillyl alcohol have been shown to be
effective agents for treating established
rodent breast (5,6) and pancreatic (7)
cancer. For example, advanced rat breast
cancer treated with limonene or perillyl
alcohol shows up to an 80% response rate,
most ofwhich are complete regressions.
We feel that the monoterpenes likely pre-
vent cancer at the progression stage by
altering very small masses ofnondetectable
early cancer cells. Thus we postulate that
the monoterpenes are an example of a
potential new class of anticancer agents
with utility that bridges prevention and
therapy. In this review, examples of this
bridging activity will be given, together
with an attempt to shed light on the cellu-




Limonene prevents both mammary and
liver cancers at the promotion/progression
stage. When mammary cancers were initi-
ated in rats by either the direct acting car-
cinogen N-methyl-N-nitrosourea or the
indirectly acting carcinogen DMBA, they
could be prevented from developing ifthe
carcinogen-exposed rats were fed limonene
starting 2 weeks after carcinogen dosing
(3). Mammary cancer with a noncarcino-
gen etiology could also be prevented by
limonene treatment. Mammary carcinomas
can be induced by the direct transduction
ofactivated ras genes into ductal epithelial
cells using retroviral vectors. Iflimonene is
given to such ras-transduced rats, the devel-
opment ofmammary carcinomas is greatly
diminished (8).
To test ifthe ability of monoterpenes
to prevent carcinogenesis during promo-
tion/progression was confined to mammary
tissue, as it is for example with tamoxifen
prevention, we explored its activity in a
liver carcinogenesis model. Rats were
treated with multiple exposures to the
hepatic carcinogen diethylnitrosamine.
Two weeks following the final exposure,
they were fed perillyl alcohol until the ter-
mination ofthe experiment. At necropsy,
the treated rats had a 90% reduction in
tumor mass compared to controls (4).
Monoterpene Tumor Therapy
In several earlychemoprevention-mammary
cancer experiments, we noticed a greater
than expected frequency of complete
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regression of mammary tumors in the
terpene-fed group. While such an observa-
tion could have several explanations, we
first tested the possibility that terpenes
could act as therapeutic molecules for rat
mammary carcinomas. We first tested the
ability oflimonene to induce the regression
of chemically induced small mammary
carcinomas, which occasionally sponta-
neously regress. We found that a large
but nontoxic dose of limonene could
cause the complete regression ofthe major-
ity of treated mammary tumors. We also
observed that advanced (> 10 mm diame-
ter) chemically induced mammary tumors,
which only rarely spontaneously regress
(5), completely regressed when treated
with limonene. Even though the large
amount (10% of diet) of limonene used
in these pair feeding studies was not toxic,
we felt that it was important to increase
the potency of the terpene to be used.
Following screening of a large variety of
natural and synthetic monoterpenes (9),
we chose to focus further studies on the
hydroxylated monocyclic monoterpene
perillyl alcohol.
Perillyl alcohol was found to be
approximately five times more potent than
limonene, but it had a similar excellent
therapeutic index at efficacious doses. Both
perillyl alcohol and limonene were very
rapidly metabolized to the same metabo-
lites-perillic acid and dihydroperillic acid.
However, rats chronically fed perillyl alco-
hol at 2% in the diets had more than twice
the serum metabolite levels than rats fed
diets containing 10% limonene (6). If
indeed the biological activity of the ter-
penes resides in their metabolites, i.e., they
are prodrugs, it is likely that perillyl alcohol
is more potent than limonene due to dif-
ferences in their pathways ofmetabolism
and their pharmacokinetics. Yet, as in most
cases, this interpretation may represent
only part ofthe mechanistic basis for dif-
ferential potency because the relative activi-
ties ofthese two compounds cannot totally
be accounted for by the ratio of their
chronic serum metabolite levels (6).
Finally, as was the case for prevention,
the therapeutic efficacy ofmonoterpenes is
not restricted to mammary carcinomas of
the rat. Recently, Stark et al. (7) showed
that perillyl alcohol was effective in a trans-
plantable pancreatic tumor model in the
hamster. They showed that nontoxic dietary
levels ofperillyl alcohol could both reduce
the growth rate ofthese tumors and cause
the complete regression ofabout a quarter
ofthese cancers. Thus it is likely that the




The monoterpenes have been shown to have
a large number ofdiverse cellular and mole-
cular effects both in vitroand in vivo. How-
ever, it is not yet apparent which ifany of
these activities are mechanistically related to
the anticancer effects ofthe monoterpenes.
We firstexamined the ability ofthe plant
monoterpenes to alter the mevalonate-lipid
metabolic pathway in mammalian cells
because monoterpenes are produced in
plants but not in mammals. These terpenes
have only minor activities at central early
parts ofthis pathway (MN Gould and Z
Ren, unpublished data). However, they
inhibit the isoprenylation ofcertain proteins
(10), the synthesis ofubiquinone (Co-Q),
and the conversion oflathesterol to choles-
terol (11). The latter two activities have the
potential to modify both cell structure and
cell energy production. Furthermore, a
reduction in Co-Qcould reduce the rate at
which free radicals aredetoxified.
The inhibition ofprotein isoprenylation,
which involves the addition of either far-
nesyl or geranyl-geranyl to the carboxyl end
ofselected proteins, could potentially mod-
ify protein function. We found in cultured
cells that the monoterpenes inhibited both
farnesylated and geranyl-geranylated pro-
teins. However, this activity was confined to
proteins with molecular weights between 20
and 26 kD. Most prenylated proteins in this
size range are small G proteins such as the
ras, rac, and rho proteins. It has been shown
that the inhibition ofprenylation reduces
the physiologic functioning ofthese pro-
teins. While these inhibitions ofprenylation
occur in cell culture as well as in enriched
enzyme preparations, both perillyl alcohol
and its metabolites perillic acid and dihy-
droperillic acid have IC50 that approach
1 mM (12). While this is only slightly
higher than the serum levels of terpene
metabolites in rats chronically fed perillyl
alcohol, it does raise the important question
ofwhether the inhibition ofprenylation
from monoterpenes is an important in vivo
mechanism in the anticancer activities of
these compounds. This question is currendy
underactive investigation.
Whether via change in prenylation or via
other signaling related activities, monoter-
pene treatment alters gene expression in
treated tumors in vivo. In monoterpene-
treated regressing tumors we have shown
changes in the cellular level ofseveral gene
products. The most well characterized to
date is the increase in the mannose 6-phos-
phate/IGF II (M6P) receptor and in the
tumor levels ofthe transforming growth fac-
tor beta (TGF-P). Increases in both these
proteins can be clearly seen by immunohis-
tochemical analysis (13). In addition, the
mRNAforM6P but notTGF-[ increases in
treated regressing tumors. In limonene
tumors that did not respond to treatment,
no changes in the mRNA level for M6P
wereobserved (13).
Both these proteins are important in
the growth control ofrodent and human
breast cancers. The M6P receptor has a
dual function. First, it helps to degrade
IGF II, which is a potent mitogen for
breast cancer. Removal of this mitogen
potentially slows tumor growth. Second,
this receptor is involved in the activation of
the secreted latent form ofTGF-P (14).
Activated TGF-, is both growth inhibitory
and differentiating in breast cancer. When
a regressing tumor is histopathologically
analyzed it is apparent both that cell divi-
sion is almost completely absent and that
the tumor is redifferentiating and remodel-
ing via an apoptotic process (Ariazi et al.,
unpublished data).
Toward Clinical Testing
Based on the favorable therapeutic ratio
observed in tumor-bearing rodents as
described above, we believe that the mono-
terpenes are potentially useful chemothera-
peutic agents that warrant testing in human
trials. Limonene is currently completing
phase I clinical trials under the direction of
C. Coombes in London (15). Because of
the low potency of this compound, it is
unlikely that a dose comparable to the rat
dose of 10% ofdiet will be achieved. Thus
in the United States, ourlaboratory, together
with the National Cancer Institute, is
beginning to examine perillyl alcohol for
clinical efficacy. At the University of
Wisconsin, we have begun clinical testing
of perillyl alcohol in advanced cancer
patients on a dose-escalating protocol. This
phase I toxicology trial will help establish
the maximum tolerated dose to be used for
future trials in which the efficacy of this
compoundwill be tested for cancer therapy.
Ifefficacy is seen in a therapeutic setting, it
will likely trigger further development and
testing ofthe monoterpenes for cancer pre-
vention. Monoterpenes are thus an example
of the development of agents that will
bridge the areas ofprevention and therapy
while, we hope, more efficiently benefiting
both areas ofanticancer research.
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